05.11.2021 – 04:14
EpiVax
Providence, RI (@ots/PRNewswire)
EpiVax, Inc. is pleased. (“EpiVax”) has entered into an important commercial license agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This is an exciting step for Maruho and EpiVax on their way to further expansion of the Tregitope program and its implementation in the clinic.
Tregitopes are immunoglobulins derived from human immunoglobulins. Tregitopes were used for the first time Discovered in 2008 By EpiVax founders Dr. Discover Anne de Groot and William Martin. Since then, EpiVax has validated numerous tregitopes and developed a robust patent portfolio for tregitopes systems. Tregitopes offer a wide range of therapeutic uses and can be co-formulated or combined with proteins to induce tolerance to a specific antigen. EpiVax is currently licensing Tregitope for additional indications with commercial and academic partners. More information about the EpiVax Tregitope platform can be found here.
Similar to intravenous immunoglobulin G (IVIG) therapy, Tregitopes can activate regulatory T cells and reduce inflammation in a variety of disease models. This mechanism of action was investigated in Academic Cooperation McGill UniversityAnd Harvard Medical SchoolAnd Unknown business partners. There have been many peer-reviewed publications on Tregitope in recent years. A full list can be found here.
Maruho will be able to use his Tregitope license to advance in-house therapeutic development strategies for autoimmune diseases. Doctor. “This agreement reflects the potential of tregitopes, natural Treg epitopes that help regulate immune responses, to treat diseases affecting patients worldwide,” said Annie de Groot, CEO of EpiVax/CSO.
About EpiVax:EpiVax is a biotechnology company specializing in T-cell cycle prediction, immune modulation, and the rapid development of vaccines. EpiVax immunoassay kits for therapeutics and vaccines, ISPRI and iVAX, are used to advance research by a number of companies around the world.
More information about EpiVax can be found at www.epivax.com.
About Maruho Co, Ltd:Maruho Co., Ltd. Headquartered in Osaka, Japan is a leading R&D, manufacturing and marketing company for dermatology products. Maruho strives to improve the health and quality of life of people all over the world.
You can find more information about https://www.maruho.co.jp/english/
For more information about Tregitope and licensing options Please contact us here.
Media contact:
Katie Porter, Business Development Manager
EpiVax
[email protected]
Logo – https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg
Original content by: EpiVax, transmitted by aktuell news
“Certified tv guru. Reader. Professional writer. Avid introvert. Extreme pop culture buff.”
More Stories
Classic espionage, cyber attacks, creating economic dependencies, and technology withdrawal –
How the technology behind ChatGPT powers this bot
Mercedes G580 with EQ technology: The G-Class has become electric